<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="at: [[inbox]]
Rheumatology - Systemic Lupus Erythematosus - Fast Facts | NEJM Resident 360 Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder with varied manifestations and severity."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle=Rheumatology - Systemic Lupus Erythematosus - Fast Facts | NEJM Resident 360"><title>Rheumatology - Systemic Lupus Erythematosus - Fast Facts | NEJM Resident 360</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.afe4548e6c13b682ece96b98cb7d656b.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.393efbe4a88743937883d8573ec5b847.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Rheumatology - Systemic Lupus Erythematosus - Fast Facts | NEJM Resident 360</h1><p class=meta>最後更新於
Feb 23, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Rheumatology%20-%20Systemic%20Lupus%20Erythematosus%20-%20Fast%20Facts%20%20NEJM%20Resident%20360.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><p>at: <a href=/inbox rel=noopener class=internal-link data-src=/inbox>inbox</a></p><a href=#rheumatology---systemic-lupus-erythematosus---fast-facts--nejm-resident-360><h1 id=rheumatology---systemic-lupus-erythematosus---fast-facts--nejm-resident-360><span class=hanchor arialabel=Anchor># </span>Rheumatology - Systemic Lupus Erythematosus - Fast Facts | NEJM Resident 360</h1></a><p>Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder with varied manifestations and severity. It most commonly occurs in women during their childbearing years and in Black, Hispanic, and Asian people more frequently and severely than in white people.</p><p>SLE can be caused directly via autoantibodies (e.g., Coombs-positive hemolytic anemia) and through immune complex deposition in various tissues, which triggers an inflammatory response (e.g., glomerulonephritis).</p><a href=#clinical-manifestations><h3 id=clinical-manifestations><span class=hanchor arialabel=Anchor># </span>Clinical Manifestations</h3></a><p>SLE is notable for its heterogeneity — patients can have SLE with different manifestations, including:</p><ul><li><p>mucocutaneous involvement</p><ul><li><p>Raynaud phenomenon</p></li><li><p>aphthous ulcers</p></li><li><p>nonscarring alopecia</p></li><li><p>numerous rashes, most of which are photosensitive:</p><ul><li><p>acute cutaneous lupus: characteristic malar or butterfly rash, but can also be generalized (at least 50% will have SLE)</p></li><li><p>subacute cutaneous lupus: psoriasiform plaques, or annular/polycyclic plaques with central clearing (all usually nonscarring; about 50% will have SLE)</p></li><li><p>chronic cutaneous lupus: most commonly discoid plaques (discoid lupus), which heal with scarring, and localized alopecia (about 25% will have SLE)</p></li></ul></li></ul></li></ul><p><strong>Examples of malar rashes in women with systemic lupus erythematosus<br>(Source: Malar Rash. N Engl J Med 2021.)</strong></p><ul><li><p>musculoskeletal involvement</p><ul><li><p>nonerosive inflammatory polyarthralgia or polyarthritis is common</p></li><li><p>myalgia</p></li><li><p>myositis</p></li><li><p>Jaccoud arthropathy</p></li></ul></li><li><p>kidney involvement</p><ul><li><p>lupus nephritis (see the 2018 Revision of the International Society of Nephrology/Renal Pathology Society classification of lupus nephritis)</p></li><li><p>renal artery or vein thrombosis in patients with a hypercoagulable state (may be associated with antiphospholipid antibodies)</p></li></ul></li><li><p>neuropsychiatric involvement</p><ul><li><p>headache</p></li><li><p>cognitive dysfunction</p></li><li><p>mood disorder</p></li><li><p>transverse myelitis</p></li><li><p>cerebral vasculitis</p></li><li><p>peripheral neuropathy</p></li><li><p>seizure</p></li></ul></li><li><p>cardiovascular involvement</p><ul><li><p>pericarditis (often asymptomatic)</p></li><li><p>myocarditis</p></li><li><p>valvular abnormalities (e.g., Libman–Sacks [nonbacterial] endocarditis)</p></li><li><p>increased risk of ischemic heart disease</p></li></ul></li><li><p>pulmonary</p><ul><li><p>pleurisy/pleural effusions</p></li><li><p>interstitial lung disease</p></li><li><p>acute lupus pneumonitis</p></li><li><p>diffuse alveolar hemorrhage (rare)</p></li><li><p>shrinking lung syndrome (pleuritic chest pain, shortness of breath, and progressive decrease in lung volume)</p></li></ul></li><li><p>hematologic involvement</p><ul><li><p>anemia, leukopenia, thrombocytopenia</p></li><li><p>hypercoagulability and antiphospholipid antibody syndrome (APLS)</p></li><li><p>gastrointestinal involvement</p></li><li><p>esophageal dysmotility</p></li><li><p>sterile peritonitis</p></li><li><p>mesenteric vasculitis</p></li><li><p>mesenteric thrombosis (in patients with APLS)</p></li><li><p>autoimmune hepatitis</p></li></ul></li></ul><a href=#diagnosis><h3 id=diagnosis><span class=hanchor arialabel=Anchor># </span>Diagnosis</h3></a><p>Diagnosis of SLE is dependent on both the characteristics listed above and the following investigations:</p><ul><li><p>laboratory studies, including complement components (C3, C4), coagulation studies with lupus anticoagulant, direct antigen test, and urine albumin or protein analysis</p></li><li><p>tests for autoantibodies</p></li><li><ul><li><p>antinuclear antibody (ANA) — highly sensitive (99%) for SLE</p></li><li><p>antibodies to Smith antigen and double-stranded DNA (dsDNA) — specific for SLE, but not sensitive</p></li><li><p>antibodies to Ro, La, and ribonucleoprotein (RNP) — not specific for SLE but if present markedly increase the chances of SLE or other ANA-associated autoimmune rheumatic disease, such as Sjögren syndrome or mixed connective tissue disease</p></li><li><p>antiphospholipid antibodies (anticardiolipin, anti-beta2-glycoprotein 1, lupus anticoagulant)</p></li><li><p>anti-dsDNA level may correlate with disease activity, in particular, lupus nephritis</p></li></ul></li></ul><p>Some patients will have serologic evidence of antibody formation and activity (such as hypocomplementemia and polyclonal hypergammaglobulinemia) that may mirror clinically active disease; in such patients, these biomarkers may be useful for monitoring disease activity. In others, these biomarkers are permanently abnormal or normal, and their monitoring utility is less useful. In other patients, there might be no evidence of complement activation or polyclonal antibody formation despite supportive serology for diagnosis. In this last group of patients, it is critical that the symptom description be weighed heavily in determining the degree of disease activity.</p><p>Additional investigations are dependent on the manifestations of disease (e.g., transthoracic echocardiography; electrocardiography; imaging of the chest, abdomen, or central nervous system; pulmonary function tests; nerve conduction studies; renal biopsy).</p><p>For decades, researchers used the American College of Rheumatology Criteria for the classification of SLE, which included 11 possible criteria. A patient was considered to have SLE if 4 criteria were positive. In 2012, an expert panel developed revised criteria that required 4 of 17 items be present, but this time at least 1 clinical and 1 immunologic criteria had to be met or the patient had to have lupus nephritis proven by biopsy with a positive ANA or anti-dsDNA test. This Systemic Lupus International Collaborating Clinics Classification (SLICC/ACR) Criteria and a 2019 update represent improved classification schemes. Although classification criteria do not always perform well in clinical practice and should not be strictly followed for diagnosis, they can be quite useful as a guide or starting point when SLE is under consideration.</p><a href=#2019-eularacr-classification-criteria-for-systemic-lupus-erythematosus><h3 id=2019-eularacr-classification-criteria-for-systemic-lupus-erythematosus><span class=hanchor arialabel=Anchor># </span>2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus</h3></a><p>*<em>§Additional criteria items within the same domain will not be counted.<br><em>Note: In an assay with at least 90% specificity against relevant disease controls<br>(Source: 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Ann Rheum Dis 2019.)</em></em></p><a href=#treatment><h3 id=treatment><span class=hanchor arialabel=Anchor># </span>Treatment</h3></a><p>In general, patients with SLE should be started on <strong>hydroxychloroquine</strong> (unless allergic, not tolerated, or the patient declines for other reasons). Hydroxychloroquine has been shown to prevent lupus flares and decreases the risk of organ damage. It may also provide an antithrombotic effect in patients with antiphospholipid syndrome and may prevent development of neonatal lupus and congenital heart block in infants of mothers with anti-Ro antibodies. Otherwise, treatment is aimed at the active manifestations of the disease.</p><p>Treatment options include the following:</p><ul><li><p>nonsteroidal anti-inflammatory drugs</p></li><li><p>glucocorticoids</p></li><li><p>antimalarial agents (especially hydroxychloroquine)</p></li><li><p>methotrexate (for inflammatory arthritis)</p></li><li><p>azathioprine</p></li><li><p>mycophenolate mofetil (MMF) or mycophenolate sodium</p></li><li><p>calcineurin inhibitors: tacrolimus, voclosporin</p></li><li><p>cyclophosphamide</p></li><li><p>B-cell–targeted therapies: rituximab (anti-CD20), belimumab (anti-BlyS)</p></li></ul><p>The following figure summarizes commonly used medications for treatment of SLE:</p><p><strong>(Source: 2019 update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus. BMJ 2019.)</strong></p><p><strong>Note:</strong> Belimumab is approved for intravenous or subcutaneous injection. For a summary of the EULAR statements and recommendations for management of SLE based on evidence and expert opinion see the 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus.</p><p><a href=/inbox rel=noopener class=internal-link data-src=/inbox>inbox</a></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li><a href=/all-list-of-resident360/ data-ctx="Rheumatology - Systemic Lupus Erythematosus - Fast Facts  NEJM Resident 360" data-src=/all-list-of-resident360 class=internal-link>all list of resident360</a></li><li><a href=/rheum/ data-ctx="Rheumatology - Systemic Lupus Erythematosus - Fast Facts  NEJM Resident 360" data-src=/rheum class=internal-link>rheumatology</a></li><li><a href=/rheumatology/ data-ctx="Rheumatology - Systemic Lupus Erythematosus - Fast Facts  NEJM Resident 360" data-src=/rheumatology class=internal-link>rheumatology</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>